SISRAM MED (01696) opened sharply higher, gaining over 4%. At the time of writing, the stock was up 4.55% to HK$4.6, with a turnover of HK$38,600. The company announced that its long-acting botulinum toxin type A product, DAXXIFY, has officially passed the quality standards inspection conducted by the National Institutes for Food and Drug Control. This milestone signifies that DAXXIFY meets the stringent requirements of the national drug regulatory system in terms of quality, safety, and efficacy, successfully completing the final critical step prior to market launch. The company believes that DAXXIFY, serving as a strategic cornerstone for its injectable filler business, will enrich the diversity of its product portfolio, providing consumers with more high-quality options. Furthermore, it is expected to act as a second growth engine, generating sustained consumable revenue for the company and solidifying its leading position in the global beauty and wellness industry.